Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Welf-Axel Geller

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Innere Medizin (Heidelberg, Germany)|April 28, 2025
Welf-Axel Geller, Johann Bauersachs, Sirka Nitschmann
Innere Medizin (Heidelberg, Germany)|March 11, 2025
[Beta-blockers in patients with preserved or mildly reduced ejection fraction after myocardial infarction]Welf-Axel Geller, Johann Bauersachs, Sirka Nitschmann
Frontiers in Cardiovascular Medicine|June 19, 2026
Early escalation of oral lipid-lowering therapy to achieve LDL-cholesterol targets in patients after myocardial infarction: study protocol for the prospective, open-label HAnnover ChOlesterol Lowering in Acute Coronary Syndrome trialAndreas Schäfer, Anika Großhennig, Leonie Theis, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Innere Medizin (Heidelberg, Germany)|April 28, 2025
Welf-Axel Geller, Johann Bauersachs, Sirka Nitschmann
Innere Medizin (Heidelberg, Germany)|March 11, 2025
[Beta-blockers in patients with preserved or mildly reduced ejection fraction after myocardial infarction]Welf-Axel Geller, Johann Bauersachs, Sirka Nitschmann
Frontiers in Cardiovascular Medicine|June 19, 2026
Early escalation of oral lipid-lowering therapy to achieve LDL-cholesterol targets in patients after myocardial infarction: study protocol for the prospective, open-label HAnnover ChOlesterol Lowering in Acute Coronary Syndrome trialAndreas Schäfer, Anika Großhennig, Leonie Theis, et al.
Pageof 1